Clinuvel Pharmaceuticals (CUV) is a biopharmaceutical company focused on developing drugs for the treatment of a range of severe skin disorders.
CUV's lead compound is SCENESSE (afamelanotide), a drug targeting erythropoietic protoporphyria (EPP).
Contact Details
Suite 3, Level 11
,
535 Bourke Street
MELBOURNE
VIC
3000
03 9660 4900
mail@clinuvel.com